GlassScriptPhysician profile
Suma Yalamanchili
NPI 1194189050
$3,705.58
in general payments reported to CMS, 2019-2025
11 companies · $1,027 in 2025
The $1,027 reported for 2025 was more than what a typical Plastic Surgery provider received nationally (typical 2025 total: $380).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $28.73 · 2023: $846 · 2024: $1,804 · 2025: $1,027.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,065 · Long Term Medical Supply Or Device Loan: $612.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,064.57 |
| Long Term Medical Supply Or Device Loan | $612.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mentor Worldwide LLC | $1,136.21 | 2023-2025 | Mentor Memorygel Resterilizable Gel Sizer, Mentor Cpx 2 Breast Tissue Expander, Artoura Breast Tissue Expander |
| Abbvie INC. | $1,065.42 | 2023-2025 | Natrelle Saline-Filled Breast Implants |
| Integra Lifesciences Corporation | $889.40 | 2023-2025 | Acell, Integra, Tenoglide |
| Axogen | $129.89 | 2023-2025 | Avance Nerve Graft |
| Baxter Healthcare | $119.46 | 2024-2025 | Perclot, Artiss |
| Motiva USA, LLC | $107.41 | 2025 | |
| Revance Therapeutics, INC. | $105.87 | 2024 | Daxxify |
| Tela Bio, INC. | $88.38 | 2025 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
| Kci USA, INC. | $28.73 | 2022 | |
| Pacira Pharmaceuticals Incorporated | $17.78 | 2025 | Exparel |
| Novo Nordisk INC | $17.03 | 2023 | Saxenda, Wegovy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suma Yalamanchili listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.